View Exam | PowerPak

1. Which of the following statements regarding adherence rates and patient response to pharmacotherapy in MDD is FALSE?

A. Response rates to initial antidepressant therapy are <50% B. Only 50% of patients remain adherent in the early phases of drug therapy C. Adherence rates to therapy improve with treatment progression D. Pharmacotherapy and psychotherapy are the most effective therapeutic options

2. According to guidelines provided by the American Psychiatric Association (APA), which of the following classes of agents is an acceptable choice as first-line therapy in most patients, including children, adolescents, and the elderly, with MDD?

A. First-generation antidepressants including tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) B. Second-generation serotonin-norepinephrine reuptake inhibitors (SNRIs) C. Second-generation selective serotonin reuptake inhibitor (SSRI) antidepressants D. Atypical antidepressants

3. Which of the following statements regarding the use of atypical antidepressants in MDD is FALSE?

A. Bupropion may have a beneficial effect in co-occurring anxiety B. Bupropion may be prescribed for patients who experience fatigue related to depression and/or in those trying to quit smoking C. Bupropion is devoid of sexual side effects and weight gain, and may be prescribed with an SSRI to counteract sexual side effects of SSRIs D. Mirtazapine is associated with drowsiness and may be beneficial in patients with insomnia E. Trazodone, nefazodone, and mirtazapine are anxiolytics and may have a beneficial effect in co-occurring anxiety

4. Choose the correct answer: Which of the following agents is a multimodal antidepressant primarily acting via inhibition of serotonin reuptake, with agonist activity at 5-HT_1Areceptors, a partial agonist activity at 5-HT_1B receptors, and an antagonist at 5-HT₃, 5-HT_1D, and 5-HT₇ receptors?

A. Vortioxetine B. Vilazodone C. Levomilnacipran D. B and C

5. According to the American Psychiatric Association (APA), patients in the acute phase of MDD should be reevaluated for treatment response after ____________ of therapy.

A. 1 week B. 2 to 3 weeks C. 4 to 6 weeks D. 7 to 8 weeks

6. Which of the following statements regarding the APA's approach to the management of pharmacotherapy in patients with MDD who do not achieve remission on initial therapy is FALSE?

A. Switching to an agent in a different class after two subsequent failures within the same class of antidepressants is recommended B. Augmentation for nonresponse or partial response to antidepressant therapy with a low-dose atypical antipsychotic or anxiolytic agent represents a viable option in lieu of switching C. The use of other antidepressants such as mirtazapine or bupropion for augmentation is supported by efficacy data D. Patients should remain on an initial antidepressant therapy for at least 12 weeks before the possibility of switching or augmentation is entertained

7. Which of the following statements regarding the role of the pharmacist in comprehensive approach to patient management in MDD is TRUE?

A. Through motivational interviewing, pharmacist-patient dialogue can directly impact medication adherence B. The pharmacist's role may include assisting PCPs in medication choice, dose, and regimen C. Pharmacist-based collaborative care interventions improve patients' attitudes toward antidepressant medications D. The APA advocates the concept of the 'therapeutic alliance' that includes pharmacist-patient interaction E. All of the above are true

8. Which of the following motivational interviewing techniques involves finding out what the patient already knows about their medication, filling in the gaps or correcting misconceptions, and exploring how the medication will fit into the patient's lifestyle?

A. Elicit-Provide-Elicit (E-P-E) B. Decisional Balance C. Reflective listening D. Open questions

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding adherence rates and patient response to pharmacotherapy in MDD is FALSE?

2. According to guidelines provided by the American Psychiatric Association (APA), which of the following classes of agents is an acceptable choice as first-line therapy in most patients, including children, adolescents, and the elderly, with MDD?

3. Which of the following statements regarding the use of atypical antidepressants in MDD is FALSE?

4. Choose the correct answer: Which of the following agents is a multimodal antidepressant primarily acting via inhibition of serotonin reuptake, with agonist activity at 5-HT_1Areceptors, a partial agonist activity at 5-HT_1B receptors, and an antagonist at 5-HT₃, 5-HT_1D, and 5-HT₇ receptors?

5. According to the American Psychiatric Association (APA), patients in the acute phase of MDD should be reevaluated for treatment response after ____________ of therapy.

6. Which of the following statements regarding the APA's approach to the management of pharmacotherapy in patients with MDD who do not achieve remission on initial therapy is FALSE?

7. Which of the following statements regarding the role of the pharmacist in comprehensive approach to patient management in MDD is TRUE?

8. Which of the following motivational interviewing techniques involves finding out what the patient already knows about their medication, filling in the gaps or correcting misconceptions, and exploring how the medication will fit into the patient's lifestyle?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding adherence rates and patient response to pharmacotherapy in MDD is FALSE?

2. According to guidelines provided by the American Psychiatric Association (APA), which of the following classes of agents is an acceptable choice as first-line therapy in most patients, including children, adolescents, and the elderly, with MDD?

3. Which of the following statements regarding the use of atypical antidepressants in MDD is FALSE?

4. Choose the correct answer: Which of the following agents is a multimodal antidepressant primarily acting via inhibition of serotonin reuptake, with agonist activity at 5-HT1A receptors, a partial agonist activity at 5-HT1B receptors, and an antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors?

5. According to the American Psychiatric Association (APA), patients in the acute phase of MDD should be reevaluated for treatment response after ____________ of therapy.

6. Which of the following statements regarding the APA's approach to the management of pharmacotherapy in patients with MDD who do not achieve remission on initial therapy is FALSE?

7. Which of the following statements regarding the role of the pharmacist in comprehensive approach to patient management in MDD is TRUE?

8. Which of the following motivational interviewing techniques involves finding out what the patient already knows about their medication, filling in the gaps or correcting misconceptions, and exploring how the medication will fit into the patient's lifestyle?

« Return to Activity

Customers who Purchased
this Activity also Purchased

4. Choose the correct answer: Which of the following agents is a multimodal antidepressant primarily acting via inhibition of serotonin reuptake, with agonist activity at 5-HT_1Areceptors, a partial agonist activity at 5-HT_1B receptors, and an antagonist at 5-HT₃, 5-HT_1D, and 5-HT₇ receptors?